Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMA-676 in Elderly AML First Relapse
NCT00003673Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 1998
- Primary completion
- Mar 1999
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Pfizer. Started Mar 1998; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003673.